This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by Weill Medical College of Cornell University
Information provided by (Responsible Party):
Weill Medical College of Cornell University Identifier:
First received: December 7, 2009
Last updated: April 27, 2017
Last verified: April 2017

The purpose of this study is to compare two different ways to administer Letrozole to determine their effectiveness in blocking estrogen production during ovarian stimulation in patients with breast cancer prior to chemotherapy/radiotherapy so that oocytes or embryos can be cryopreserved and patients can possibly achieve a pregnancy after the treatment of breast cancer.

During standard ovulation stimulation, the estrogen levels will exceed normal levels and may reach 10 times the normal level for a 2 week period. This may not be desirable in breast cancer patients. The study hopes to determine if the investigators can stimulate oocyte development in the conventional way and administer different doses of Letrozole as the oocytes develop, to keep estradiol levels low, increase the number of oocytes the investigators are able to recover, and improve the quality of those oocytes.

Condition Intervention
Breast Cancer Infertility Drug: Letrozole

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Randomized Open Label Clinical Trial of Fixed Dose Letrozole vs. Titrated Letrozole for In Vitro Fertilization With Cryopreservation of Oocytes and Embryos in Breast Cancer Patients

Resource links provided by NLM:

Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:
  • percent of mature oocyte yield [ Time Frame: 1-2 month ]
    The percentage of mature oocyte obtained will be compared from both arms.

Estimated Enrollment: 50
Study Start Date: November 2009
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: October 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Titrated dose Letrozole
Patients who are randomized to the titrated dose of Letrozole, will start gonadotropins in the evening of day #2 of their menstrual cycle with injectable follicle stimulating hormone (FSH) and human menopausal gonadotropin (HMG). Oral Letrozole will be added to the stimulation in the following titrated regimen.
Drug: Letrozole

Letrozole titrated regimen may be started on day 2 of menstrual cycle:

Serum Estradiol level <150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level >350 pg/ml - 7.5 mg;

Other Name: Femara- trade name
Active Comparator: Fixed dose Letrozole
Patients who are randomized to fixed dose Letrozole will start Letrozole 5mg daily (orally) on the second day of their menstrual cycle and then gonadotropins on the fourth day of their menstrual cycle.
Drug: Letrozole
Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
Other Name: Femara- trade name

  Show Detailed Description


Ages Eligible for Study:   19 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female breast cancer patient with breast cancer diagnosis after surgery and before undergoing chemotherapy desiring fertility preservation with oocyte or embryo cryopreservation
  • Healthy subject according to documented medical history and physical examination who has been diagnosed with breast cancer (estrogen and progesterone receptor positive and/or negative)
  • Age less that 45 years at time of informed consent
  • Verbal or written clearance from medical or surgical oncologist to undergo controlled ovarian hyperstimulation-IVF
  • Delay to chemotherapy treatment will not jeopardize cancer treatment outcome
  • Ovarian stimulation will not affect cancer treatment plan
  • Transvaginal ultrasound scan (US) within one month of starting stimulation with no clinically significant pelvic mass
  • Serum FSH level (Day 2-4) less than 25
  • Negative pregnancy test prior to beginning Letrozole or gonadotropin therapy
  • Willing and able to comply with the protocol
  • Voluntary provision of written informed consent, prior to any study related procedure that was not part of normal medical care, with the understanding that the subject can withdraw consent at any time without prejudice to her future medical care
  • Willingness to provide follow-up information on herself and babies born as part of this study

Exclusion Criteria:

  • Patients not medically cleared by their oncologist
  • Patients with stage IV breast cancer based on the poor prognosis, general health of the patient, and higher uncertainty with delaying chemotherapy
  • Any clinically relevant abnormal laboratory value (FSH >25 miu/ml, renal function, (greater than two times normal value), hepatic function (greater than two times normal value), blood biochemistry, hematology (elevated white blood count greater than 1.5 times the normal value, hemoglobin <10mg/dL, thrombocytopenia), abnormal cholesterol profile (total cholesterol ≥ 300mg/dL, abnormal LDL greater than 2 times normal value,) based on a fasting sample during the screening phase
  • Contraindications for the use of gonadotropins (i.e. Tumors other than breast cancer, pregnancy, lactation, undiagnosed vaginal bleeding)
  • Recent or current medical conditions where the patient is not medically stable to undergo stimulation or egg retrieval, HIV infection, diabetes, cardiovascular disease, gastrointestinal, hepatic disease, undiagnosed pelvic mass, renal or pulmonary disease
  • History or presence of alcohol or drug abuse within 12 months of signing consent
  • History of severe allergic or anaphylactic reactions or hypersensitivity to any of the concomitant medication prescribed as part of the treatment regimen in this protocol
  • Administration of investigational drugs within three months prior to signing the informed consent
  • Use of insulin sensitizing agents at least one month prior to signing informed consent
  • Any patient who is not a candidate for IVF
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01035099

Contact: Eden Rauch, MD 646-962-3327
Contact: Rodriq Stubbs, NP 646-962-3276

United States, New York
Weill Cornell Medical College Recruiting
New York, New York, United States, 10021
Contact: Eden Rauch, MD    646-962-3327   
Contact: Rodriq Stubbs, NP    646-962-3276   
Principal Investigator: Glenn Schattman, MD         
Sponsors and Collaborators
Weill Medical College of Cornell University
Principal Investigator: Glenn Schattman, MD Weill Cornell Medical Cornell
  More Information

Additional Information:
Responsible Party: Weill Medical College of Cornell University Identifier: NCT01035099     History of Changes
Other Study ID Numbers: WCMC-0075
Study First Received: December 7, 2009
Last Updated: April 27, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Weill Medical College of Cornell University:
IVF (in vitro fertilization)
Fertility Preservation
Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Genital Diseases, Male
Genital Diseases, Female
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on July 27, 2017